Kala Pharmaceuticals Inc
KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company's lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical d… Read more
Market Cap & Net Worth: Kala Pharmaceuticals Inc (KALA)
Kala Pharmaceuticals Inc (NASDAQ:KALA) has a market capitalization of $7.02 Million ($7.02 Million) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #34157 globally and #11135 in its home market, demonstrating a -3.22% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Kala Pharmaceuticals Inc's stock price $0.25 by its total outstanding shares 27849725 (27.85 Million).
Kala Pharmaceuticals Inc Market Cap History: 2017 to 2026
Kala Pharmaceuticals Inc's market capitalization history from 2017 to 2026. Data shows change from $25.75 Billion to $7.02 Million (-61.22% CAGR).
Index Memberships
Kala Pharmaceuticals Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.00% | #858 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #2716 of 3165 |
Weight: Kala Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Kala Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Kala Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
272.99x
Kala Pharmaceuticals Inc's market cap is 272.99 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $5.14 Billion | $6.07 Million | -$94.35 Million | 845.95x | N/A |
| 2020 | $9.44 Billion | $6.36 Million | -$104.33 Million | 1483.98x | N/A |
| 2021 | $1.68 Billion | $11.24 Million | -$142.60 Million | 149.90x | N/A |
| 2022 | $1.06 Billion | $3.89 Million | -$44.82 Million | 272.99x | N/A |
Competitor Companies of KALA by Market Capitalization
Companies near Kala Pharmaceuticals Inc in the global market cap rankings as of March 18, 2026.
Key companies related to Kala Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Kala Pharmaceuticals Inc Historical Marketcap From 2017 to 2026
Between 2017 and today, Kala Pharmaceuticals Inc's market cap moved from $25.75 Billion to $ 7.02 Million, with a yearly change of -61.22%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $7.02 Million | -54.65% |
| 2025 | $15.48 Million | -91.99% |
| 2024 | $193.28 Million | -0.86% |
| 2023 | $194.95 Million | -81.65% |
| 2022 | $1.06 Billion | -36.94% |
| 2021 | $1.68 Billion | -82.15% |
| 2020 | $9.44 Billion | +83.74% |
| 2019 | $5.14 Billion | -24.54% |
| 2018 | $6.81 Billion | -73.55% |
| 2017 | $25.75 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Kala Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $7.02 Million USD |
| MoneyControl | $7.02 Million USD |
| MarketWatch | $7.02 Million USD |
| marketcap.company | $7.02 Million USD |
| Reuters | $7.02 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.